Heat Biologics Inc (NASDAQ:HTBX) shares fell over 65% this month, after the firm’s Phase II data read-out from its HS-410 bladder cancer trial …
Yesterday, Palatin Technologies, Inc. (NYSEMKT:PTN) announced its fiscal first quarter results for 2017, with Roth Capital analyst Joseph Pantginis determining that “all eyes” …
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Sophiris Bio Inc (NASDAQ:SPHS) with …
In a research report published Tuesday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a price target of $7.
In a research report released Tuesday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Neuralstem, Inc. (NASDAQ:CUR) with a price …
Palatin Technologies, Inc. (NYSEMKT:PTN) shares were on a close to 18% rise after market close yesterday after the firm’s pipeline drug bremelanotide (BMT), …
In a research report released Tuesday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Neuralstem, Inc. (NASDAQ:CUR) with a price target …
Roth Capital analyst Joseph Pantginis initiates coverage on shares of Sophiris Bio Inc (NASDAQ:SPHS) as the analyst provides a closer look at the …
Roth Capital analyst Joseph Pantginis was out today with a research note on Peregrine Pharmaceuticals (NASDAQ:PPHM), after the drug-maker announced financial results for the fourth …
In a research report published today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Cytokinetics Inc. (NASDAQ:CYTK), with a price …
